Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression

References

• Inai K. Pathology of Mesothelioma. Japanese J Lung Cancer 2007; 47:223–232.
   Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-44; PMID:12860938; http://dx.doi.org/10.1200/JCO.2003.11.136
   Google Scholar
• Remon J, Lianes P, Martinez S, Velasco M, Querol R, Zanui M. Malignant mesothelioma: new insights into a rare disease. Cancer Treat Rev 2013; 39:584-91; PMID:23276688; http://dx.doi.org/10.1016/j.ctrv.2012.12.005
   Google Scholar
• Tsao AS. Mesothelioma. J Thorac Oncol 2012; 7:S399-400; PMID:23160333; http://dx.doi.org/10.1097/JTO.0b013e31826df254
   Google Scholar
• Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A. Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 2010; 36:24-32; PMID:19879055; http://dx.doi.org/10.1016/j.ctrv.2009.09.003
   Google Scholar
• Okamoto I, Fukuoka M. S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2009; 10:290-4; PMID:19632949; http://dx.doi.org/10.3816/CLC.2009.n.040
   Google Scholar
• Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996; 56:2602-6; PMID:8653704
   Google Scholar
• Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 2010; 28:5240-6; PMID:21079147; http://dx.doi.org/10.1200/JCO.2010.31.0326
   Google Scholar
• Yoshioka H, Okamoto I, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Atagi S, Hirashima T, et al. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. Annals Oncol 2013; 24:1326-31; http://dx.doi.org/10.1093/annonc/mds629
   Google Scholar
• Hamamoto Y. Better efficacy of S-1 treatment for thymic carcinoma: case report and review of the literature. Int Cancer Conference J 2013; 2:17–21; http://dx.doi.org/10.1007/s13691-012-0056-8
   Google Scholar
• Kaira K, Ohde Y, Nakagawa K, Okumura T, Murakami H, Takahashi T, Kondo H, Nakajima T, Endo M, Yamamoto N. Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma. Medical Oncol 2012; 29:1663-72; http://dx.doi.org/10.1007/s12032-011-0069-8
   Google Scholar
• Okuma Y, Shimokawa T, Takagi Y, Hosomi Y, Iguchi M, Okamura T, Shibuya M. S-1 is an active anticancer agent for advanced thymic carcinoma. Lung cancer (Amsterdam, Netherlands) 2010; 70:357-63; PMID:20951466; http://dx.doi.org/10.1016/j.lungcan.2010.09.004
   Google Scholar
• Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995; 108:1122-8; PMID:7555126; http://dx.doi.org/10.1378/chest.108.4.1122
   Google Scholar
• Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Annals Oncol 2004; 15:257-60; http://dx.doi.org/10.1093/annonc/mdh059
   Google Scholar
• Inai K. Pathology of mesothelioma. Environmental Health Preventive Med 2008; 13:60-4; http://dx.doi.org/10.1007/s12199-007-0017-6
   Google Scholar
• Nakano J, Huang C, Liu D, Masuya D, Nakashima T, Yokomise H, Ueno M, Wada H, Fukushima M. Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT. Br J Cancer 2006; 95:607-15; PMID:16880781; http://dx.doi.org/10.1038/sj.bjc.6603297
   Google Scholar
• Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, et al. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 2010; 28:3746-53; PMID:20625125; http://dx.doi.org/10.1200/JCO.2009.27.4662
   Google Scholar
• Kaira K, Serizawa M, Koh Y, Miura S, Kaira R, Abe M, Nakagawa K, Ohde Y, Okumura T, Murakami H, et al. Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors. Lung Cancer 2011; 74:419-25; PMID:21550686; http://dx.doi.org/10.1016/j.lungcan.2011.04.001
   Google Scholar
• Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366:397-408; PMID:16054941; http://dx.doi.org/10.1016/S0140-6736(05)67025-0
   Google Scholar
• Fukui Y, Oka T, Nagayama S, Danenberg PV, Danenberg KD, Fukushima M. Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med 2008; 22:709-16; PMID:19020767
   Google Scholar
• Van TT, Hanibuchi M, Kakiuchi S, Sato S, Kuramoto T, Goto H, Mitsuhashi A, Nishioka Y, Akiyama S, Sone S. The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Cancer Chemotherapy Pharmacol 2011; 68:497-504; http://dx.doi.org/10.1007/s00280-010-1503-x
   Google Scholar
• Christoph DC, Asuncion BR, Mascaux C, Tran C, Lu X, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Neumann V, et al. Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma. J Thorac Oncol 2012; 7:1440-8; PMID:22895141; http://dx.doi.org/10.1097/JTO.0b013e318260deaa
   Google Scholar
• Sakamoto E, Nagase H, Kobunai T, Oie S, Oka T, Fukushima M, Oka T. Orotate phosphoribosyltransferase expression level in tumors is a potential determinant of the efficacy of 5-fluorouracil. Biochem Biophysical Res Communications 2007; 363:216-22; http://dx.doi.org/10.1016/j.bbrc.2007.08.164
   Google Scholar
• Diasio RB. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology 1998; 12:23-7; PMID:9830621
   Google Scholar
• Calvert AH. Biochemical Pharmacology of Pemetrexed. Oncology 2004; 18:13-7; PMID:15655931
   Google Scholar
• Lustgarten DE, Deshpande C, Aggarwal C, Wang LC, Saloura V, Vachani A, Wang LP, Litzky L, Feldman M, Creaney J, et al. Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma. J Thorac Oncol 2013; 8:469-77; PMID:23486267; http://dx.doi.org/10.1097/JTO.0b013e318283da3e
   Google Scholar
• Mairinger F, Vollbrecht C, Halbwedl I, Hatz M, Stacher E, Gully C, Quehenberger F, Stephan-Falkenau S, Kollmeier J, Roth A, et al. Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma. J Thorac Oncol 2013; 8:644-53; PMID:23449276; http://dx.doi.org/10.1097/JTO.0b013e318287c224
   Google Scholar